Drug delivery system for the subconjunctival administration of fine grains

• US 20050089545A1
• Filed: 02/21/2003
• Published: 04/28/2005
• Est. Priority Date: 02/22/2002
• Status: Abandoned Application

• Current Assignee: Santen Pharmaceutical Company Limited
• Original Assignee: Santen Pharmaceutical Company Limited
• Inventors: Yamada, Kazuhito, Kuwano, Mitsuaki
• Application Number:
  US10/505,393
• Publication Number:
  US 20050089545A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention provides an excellent drug delivery system to posterior segments. An injection according to the present invention is a periocular injection which comprises fine particles containing a drug and enables the drug to deliver to the posterior segments. The drug can be efficiently delivered to the posterior segments (such as a retina, a choroid and an optic nerve) while scarcely injuring ophthalmic tissues by administering the fine particles containing the drug periocularlly. Preferred fine particles are made of a synthetic biodegradable polymer, their average particle diameter is 50 nm to 150 μm, and the drug is dispersed in the fine particles uniformly. Preferred drugs are anti-inflammatories, immunosuppressors, antivirals, anticancer drugs, angiogenesis inhibitors, optic neural protectants, antimicrovials and antifungal agents.

Claims

1. A drug delivery system to a posterior segment characterized in that fine particles containing a drug are periocularlly administered.

3. The drug delivery system as claimed in claim 1, wherein an average particle diameter of the fine particles is 50 nm to 150 μ

m.

4. The drug delivery system as claimed in claim 1, wherein the fine particles are made of a biodegradable or biosoluble polymer.

5. The drug delivery system as claimed in claim 1, wherein the posterior segment is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

6. The drug delivery system as claimed in claim 1, wherein the drug is a drug for treatment or prevention of a disease of a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

7. The drug delivery system as claimed in claim 1, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrovial or an antifungal agent.

2. A periocular injection which comprises fine particles containing a drug and enables the drug to deliver to a posterior segment.

13. The periocular injection as claimed in claim 2, wherein an average particle diameter of the fine particles is 50 nm to 150 μ

m.

14. The periocular injection as claimed in claim 2, wherein the fine particles are made of a biodegradable or biosoluble polymer.

15. The periocular injection as claimed in claim 2, wherein the posterior segment is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

16. The periocular injection as claimed in claim 2, wherein the drug is a drug for treatment or prevention of a disease of a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

17. The periocular injection as claimed in claim 2, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrovial or an antifungal agent.

8. A method of treating and/or preventing a disease of a posterior segment comprising administering periocularlly to a patient an effective amount for treatment of an injection comprising fine particles containing a drug.

9. The method of treating and/or preventing the disease of the posterior segment as claimed in claim 8, wherein an average particle diameter of the fine particles is 50 nm to 150 μ

m.

10. The method of treating and/or preventing the disease of the posterior segment as claimed in claim 8, wherein the fine particles are made of a biodegradable or biosoluble polymer.

11. The method of treating and/or preventing the disease of the posterior segment as claimed in claim 8, wherein the posterior segment is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

12. The method of treating and/or preventing the disease of the posterior segment as claimed in claim 8, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrovial or an antifungal agent.